The role of the Glucocorticoid Receptor (GR) and the Androgen Receptor (AR) in Triple Negative Breast Cancer in re-sponse to DNA damaging chemotherapy treatment: UNDERGRADUATE RESEARCH IN NATURAL AND CLINICAL SCIENCE AND TECHNOLOGY (URNCST) JOURNAL

Sinead Donnelly, Niamh E Buckley

Research output: Contribution to conferencePoster

Abstract

Aims and Objectives: Triple negative breast cancer (TNBC) is a type of breast cancer that does not express the oestrogen receptor (ER), the progesterone receptor (PR) and does not haveamplification of the human epidermal growth factor receptor 2 (HER-2). It is an aggressive form of breast cancer which has poor clinical outcomes. Currently, the standard of care for TNBC patients is DNA damaging chemotherapy, which has a variable response rate. This study aims to evaluate the role of the androgen receptor (AR) and the glucocorticoid receptor (GR) in TNBC, and their ability to modulate DNA damaging chemotherapy and anti-microtubule agents.Methods: GR expression was evaluated through in silico analysis using in house and external data sets. TNBC cell lines were modulated, using both siRNA (ARsi and GRsi) and pharmacological modulation (GR agonist Dexamethasone GR an-tagonist Mifepristone, AR antagonists Bicalutamide and Enzalutamide). Statistical analysis was carried out using Prism 5.Results: In silicoanalysis showed that high GR expression was associated with improved clinical outcome versus patients with low GR expression. In TNBC cell lines treated with DNA damaging agents, the GR agonist Dexamethasone increases sensitivity to chemotherapy. Dexamethasone is used to attenuate chemotherapy related side effects in TNBC patients, and may therefore be modulating response. Conversely, in TNBC cells treated with anti-microtubule agents, Dexamethasone de-creased sensitivity to chemotherapy.Conclusion: This study recommends that TNBC patients receiving DNA damaging chemotherapy may benefit from the ad-dition of Dexamethasone. Those receiving anti-microtubule agents should be given an alternative anti-emetic, as Dexame-thasone reduced sensitivity to this chemotherapy
Original languageEnglish
PagesA22
DOIs
Publication statusPublished - 2018
EventStudent Medical Summit - University College Dublin, Dublin, Ireland
Duration: 03 Feb 2018 → …

Conference

ConferenceStudent Medical Summit
CountryIreland
CityDublin
Period03/02/2018 → …

Fingerprint Dive into the research topics of 'The role of the Glucocorticoid Receptor (GR) and the Androgen Receptor (AR) in Triple Negative Breast Cancer in re-sponse to DNA damaging chemotherapy treatment: UNDERGRADUATE RESEARCH IN NATURAL AND CLINICAL SCIENCE AND TECHNOLOGY (URNCST) JOURNAL'. Together they form a unique fingerprint.

Cite this